clinical trials drug development fragile X syndrome

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective

Authors: Anna W Lee, Dejan Budimirovic, Elizabeth Berry-Kravis, Jeannie Visootsak, Pamela Ventola

Journal: Brain Sciences

Year Published: 2018

Abstract Fragile X syndrome (FXS) is the leading known cause of inherited intellectual disability and autism spectrum disorder. It is caused by a mutation of the fragile X mental retardation 1 (FMR1) gene, resulting in a […]

Back to Publications